Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | ADI-270 |
Trade Name | |
Synonyms | ADI270|ADI 270 |
Drug Descriptions |
ADI-270 comprises allogeneic T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD70 and containing a dominant negative form of the TGFBR2, which potentially increases antitumor immune activity against CD70-expressing tumors (Journal for ImmunoTherapy of Cancer 2024;12). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | NA |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
ADI-270 | ADI-270 | 0 | 1 |